PD-L1

[International Immunopharmacology] Scientists examined the efficacy of TY101 as an anti-tumor immune reagent combined with HMGN1and R848.

[Signal Transduction and Targeted Therapy] Fusobacterium nucleatum induces different immune responses in colorectal cancer (CRC) with different microsatellite-instability statuses. Scientists investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC.

[Hepatic Cell News] Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.

[Scientific Reports] Scientists used mammary tumors with in situ immunomodulation consisting of intratumoral injections of Flt3L to mobilize conventional type-1 dendritic cells (cDC1s), local irradiation to induce immunogenic tumor cell death, and TLR3/CD40 stimulation to activate cDC1s.

[PLoS One] Whole blood was collected at serial timepoints from metastatic breast cancer patients and healthy donors for circulating tumor cell and platelet PD-L1 analysis with a phycoerythrin-labeled anti-human PD-L1 monoclonal antibody using the CellSearch® assay.

[Journal of Biomedical Science] Scientists applied three colon cancer cell lines, including microsatellite stable cell lines, which are SW480 and SW620, and microsatellite instability-high cell line, which is DLD-1.